Latest Healthcare It News

ECS Botanics has successfully raised nearly A$2 million through a placement aimed at accelerating its international expansion and product development. The move underscores growing investor confidence in the medicinal cannabis company’s strategic growth plans.

Anteris Technologies has gained FDA approval to start patient recruitment in the US for its pivotal PARADIGM Trial, following initial European regulatory success. The company advances manufacturing and clinical readiness as it pushes toward key regulatory milestones.

Anteris Technologies Global Corp. reported a $22.2 million loss in Q3 2025 while progressing its DurAVR Transcatheter Heart Valve pivotal trial following key regulatory approvals. The company bolstered its cash position with a $25.2 million private placement post-quarter.

Unith Ltd has secured new contracts and expanded its strategic partnerships while advancing its ISO 27001 certification, signaling strong momentum in its AI digital human technology business.

Navigator Global Investments (NGI) reveals a robust business model focused on minority stakes in alternative asset managers, supported by strategic partnerships and a diversified portfolio. The company targets doubling its EBITDA by 2030 amid strong industry tailwinds.

Immutep Limited’s Phase II EFTISARC-NEO trial reveals a novel immunotherapy combo delivering a striking 51.5% tumour response in soft tissue sarcoma patients, alongside robust immune activation signals.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.

Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.

BPH Global Ltd is pioneering a novel seaweed-based natural formulation targeting male vitality, staking a first-mover claim in this emerging segment of men’s health. The company’s R&D, led by Gaia Mariculture, aims to launch an OTC supplement with potential for clinical validation.

Proteomics International Laboratories has secured a $2.2 million Australian Government R&D tax rebate, reinforcing its financial position as it advances a promising pipeline of diagnostic tests based on its proprietary Promarker® technology.

dorsaVi Limited has acquired a cutting-edge neuromorphic processing-in-memory technology portfolio, positioning itself at the forefront of next-generation wearable and robotics intelligence. This strategic move, coupled with leadership changes, signals a new era for the company’s adaptive biosensor and robotics platforms.

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.